Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Appoints Dr. Hua Jiang as Executive Director

Haematologica Publishes Results from the Investigator-Initiated Trials of CARsgen's CT053 BCMA CAR T-Cell Therapy in Multiple Myeloma

CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen’s CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers

CARsgen to Present Two Clinical Trials of CT041 at ASCO Annual Meeting

CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China